Literature DB >> 16603729

Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation.

Janardan K Reddy1, M Sambasiva Rao.   

Abstract

Fatty liver disease (FLD), whether it is alcoholic FLD (AFLD) or nonalcoholic FLD (NAFLD), encompasses a morphological spectrum consisting of hepatic steatosis (fatty liver) and steatohepatitis. FLD has the inherent propensity to progress toward the development of cirrhosis and hepatocellular carcinoma. It is generally difficult to distinguish AFLD from NAFLD on morphological grounds alone despite the distinctions implied by these etiological designations. The indistinguishable spectrum of histological features of both AFLD and NAFLD suggests a possible convergence of pathogenetic mechanisms at some critical juncture that enables the progression of steatohepatitis toward cirrhosis and liver cancer. From a pathogenetic perspective, FLD may be considered a single disease with multiple etiologies. Excess energy consumption and reduced energy combustion appear to be critical events that culminate in lipid storage in the liver. Energy combustion in the liver is controlled by peroxisome proliferator-activated receptor (PPAR)-alpha-regulated mitochondrial and peroxisomal fatty acid beta-oxidation systems and the microsomal omega-oxidation system. PPAR-alpha, a receptor for peroxisome proliferators, functions as a sensor for fatty acids (lipid sensor), and ineffective PPAR-alpha sensing can lead to reduced energy burning resulting in hepatic steatosis and steatohepatitis. Delineation of the pathogenetic aspects of FLD is necessary for developing novel therapeutic strategies for this disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16603729     DOI: 10.1152/ajpgi.00521.2005

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  255 in total

1.  The prevalence and adverse profiles of fatty liver disease among different ethnic public servants in Urumqi of Xinjiang Uygur Autonomous Region in China.

Authors:  Dan Chen; Jie Guan; Xiang Xie; Wei-Yun Zhao; Palida Abulaiti; Yu Wang; Zhi-Qin Cheng; Jing Zhang; Ying Gao
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 2.  The Hepatic Lipidome: A Gateway to Understanding the Pathogenes is of Alcohol-Induced Fatty Liver.

Authors:  Robin D Clugston; Madeleine A Gao; William S Blaner
Journal:  Curr Mol Pharmacol       Date:  2017       Impact factor: 3.339

Review 3.  Stable isotope-based flux studies in nonalcoholic fatty liver disease.

Authors:  Arthur McCullough; Stephen Previs; Takhar Kasumov
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

Review 4.  Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Xue-Qun Zhang; Cheng-Fu Xu; Chao-Hui Yu; Wei-Xing Chen; You-Ming Li
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

5.  Rats selectively bred for low aerobic capacity have reduced hepatic mitochondrial oxidative capacity and susceptibility to hepatic steatosis and injury.

Authors:  John P Thyfault; R Scott Rector; Grace M Uptergrove; Sarah J Borengasser; E Matthew Morris; Yongzhong Wei; Matt J Laye; Charles F Burant; Nathan R Qi; Suzanne E Ridenhour; Lauren G Koch; Steve L Britton; Jamal A Ibdah
Journal:  J Physiol       Date:  2009-02-23       Impact factor: 5.182

6.  Methionine deficiency and hepatic injury in a dietary steatohepatitis model.

Authors:  Helieh S Oz; Theresa S Chen; Manuela Neuman
Journal:  Dig Dis Sci       Date:  2007-08-21       Impact factor: 3.199

7.  Rectification of impaired adipose tissue methylation status and lipolytic response contributes to hepatoprotective effect of betaine in a mouse model of alcoholic liver disease.

Authors:  Xiaobing Dou; Yongliang Xia; Jing Chen; Ying Qian; Songtao Li; Ximei Zhang; Zhenyuan Song
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

8.  Quantum coherence spectroscopy to measure dietary fat retention in the liver.

Authors:  Lucas Lindeboom; Robin A de Graaf; Christine I Nabuurs; Petronella A van Ewijk; Matthijs Kc Hesselink; Joachim E Wildberger; Patrick Schrauwen; Vera B Schrauwen-Hinderling
Journal:  JCI Insight       Date:  2016-08-18

9.  5-cholesten-3β,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model.

Authors:  Leyuan Xu; Jin Koung Kim; Qianming Bai; Xin Zhang; Genta Kakiyama; Hae-Ki Min; Arun J Sanyal; William M Pandak; Shunlin Ren
Journal:  Mol Pharmacol       Date:  2012-12-20       Impact factor: 4.436

10.  Optimal utilization of extended hepatic grafts.

Authors:  Sherilyn Gordon Burroughs; Ronald W Busuttil
Journal:  Surg Today       Date:  2009-09-24       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.